Authors

Latest:

Dr Monk on the Investigation of B7-H4–Directed Vedotin ADCs in Gynecologic Cancers

Bradley Monk, MD, FACS, FACOG, discusses the rationale for investigating B7-H4–directed vedotin antibody-drug conjugates and highlights how these agents may address unmet needs for patients with gynecologic cancers.

Anirudh Rai, MD

Latest:

Empowering Community Cancer Care: Importance of Collaboration

In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.

Guillermo Garcia-Manero, MD

Latest:

Dr Garcia-Manero on Dual IRAK4/FLT3 Inhibition With Emavusertib in MDS and AML

Guillermo Garcia-Manero, MD, discusses the rationale for investigating the dual inhibition of IRAK4 and FLT3 with emavusertib in MDS and AML

Alexander Putnam Cole, MD

Latest:

Dr Cole on the Rationale for Investigating Race-based Disparities in Prostate Cancer–Specific Survival

Alexander Putnam Cole, MD, discusses the rationale for investigating the magnitude of racial and ethnic disparities in prostate cancer–specific survival in patients undergoing surgery vs radiotherapy.

James Catto, MB, ChB, PhD, FRCS

Latest:

Dr Catto on the Utility of Erdafitinib in High-Risk nMIBC With FGFR Alterations

James Catto, MB, ChB, PhD, FRCS, discusses the utility of erdafitinib in patients with high-risk non–muscle-invasive bladder cancer with select FGFR alterations who have received prior treatment with Bacillus Calmette–Guérin.

Zaraq Khan, MBBS

Latest:

Dr. Khan on the Ideal Patients for GnRH Agonists in Breast Cancer

Zaraq Khan, MBBS, discusses which patients with breast cancer would be ideal candidates to receive treatment with a GnRH agonist for ovarian protection.

Nicolaus Kröger, MD

Latest:

Dr. Kröger on Toxicities Associated With Allogeneic Stem Cell Transplant in Myeloma

Nicolaus Kröger, MD, discusses toxicities associated with allogeneic stem cell transplant in patients with multiple myeloma.

Neil M. Iyengar, MD

Latest:

T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.

Benjamin Garmezy, MD

Latest:

Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer

Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.

Renata Ferrarotto

Latest:

Dr. Ferrarotto on the Mechanism of Action of Trilaciclib in ES-SCLC

Renata Ferrarotto, MD, discusses the mechanism of action of trilaciclib in extensive-stage small cell lung cancer.

Jun Ma, MD

Latest:

Dr Ma on Sintilimab Plus Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Jun Ma, MD, discusses findings from the phase 3 CONTINUUM trial of sintilimab in combination with induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

Alec Watson, MD

Latest:

Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD

Fernando C. Maluf, MD, PhD

Latest:

Dr Maluf on Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer

Fernando C. Maluf, MD, PhD discusses the efficacy of platinum-based chemotherapy plus pembrolizumab in advanced penile squamous cell carcinoma.

Jeffrey P. Townsend, PhD

Latest:

Dr Townsend on the Future Analysis of Prostate Cancer Driver Mutations Using Neoplasm Tissue Samples

Jeffrey P. Townsend, PhD, discusses analysis of prostate cancer driver mutations using early neoplasm tissue samples.

Wenyin Shi, MD, PhD

Latest:

Dr. Shi on the Rationale to Evaluate a Tumor-Treating Fields Therapy–Based Combination in Glioblastoma

Wenyin Shi, MD, PhD, discusses the rationale to evaluate a tumor-treating fields therapy in combination with temozolomide and radiation therapy in glioblastoma.

Christopher M. Gallagher, MD

Latest:

Dr Gallagher on Unmet Needs With ADCs in Breast Cancer

Christopher M. Gallagher, MD, discusses unmet needs surrounding the use of antibody-drug conjugates, as well as questions remaining with other approved agents in breast cancer.

Yungan Tao, MD

Latest:

Dr Tao on the Efficacy of Avelumab/Cetuximab/Radiotherapy in Cisplain-Eligibile vs Ineligible HNSCC

Yungan Tao, MD, discusses the efficacy of avelumab plus cetuximab and radiotherapy in patients with head and neck squamous cell carcinoma.

Elizabeth Prechtel Dunphy, DNP, CRNP, AOCN

Latest:

Novel Clinical Trials With ADCs in Gastric Cancer

Before closing out their discussion on HER2+ gastric cancer, experts review clinical trials investigating other novel ADC agents in this setting.

Mohamad Mohty, MD, PhD

Latest:

Dr Mohty on the Potential Role of BCMA-Targeted Bispecific Antibodies in Myeloma

Mohamad Mohty, MD, PhD, discusses the potential role of BCMA-targeted bispecific antibodies in myeloma.

Danja Sarink, PhD

Latest:

Overcoming Racial Inequality in Epithelial Ovarian Cancer Research

Danja Sarink, PhD, discusses the importance of studying race and ethnicity in epithelial ovarian cancer research.